吼一声：如果想赌CANCER 疫苗的进

xxtrader

DNDN,HALTED了，14：20马上公布消息，我手上还捏了5000股，早上已经套利了一半，5000股，不敢太冒险，但我还是看好这个前列腺癌症疫苗

如果买不到DNDN的，赶紧去进点ONTY,刚才曾一度最低价格3.32，气死俺了，俺钓鱼挂了个单10000股3.30，就差2分没FILLED,只好按市场价格追买，瞬间就过3.5了买在3.719，现在应该已经4块多了，也是个出肺癌疫苗的公司，会被DNDN消息影响

xiaobailong

summer123

Shares of Dendreon Corporation (NASDAQ:DNDN) plummeted nearly 15 points within a two minute period before being halted pending news from the company. Investors had been anticipating a 3:20pm[/b] release of data relating to Provenge, an experimental prostate cancer drug. As of yesterday's closing price of $21.55, shares were up over 370% year-to-date on Provenge speculation.

summer123

Cancer
Data Shows Provenge Extends Cancer Survival
Matthew Herper, 04.28.09, 02:01 PM EDT
Dendreon released some data on its prostate cancer drug, Provenge.

CHICAGO -- Dendreon released some data related to its prostate cancer drug Provenge ahead of a data presentation here at the American Urological Association.

The data show that Provenge, the company's immunotherapy for prostate cancer, extended survival in a clinical trial by a median 4.1 months, reducing the risk of death by 22.5% in a 500-person study.

The result is unlikely to be due to chance. Its statistical p-value is 0.032, meaning roughly that there is only a three in 100 chance the result happened randomly. Scientists generally assume results with a p value of less than one in 100 are trustworthy.

A press release from the AUA also states that the number of patients who are alive three years after treatment is 38% greater among those who received Provenge.

That's surprising, says Donald Berry, a statistician at M.D. Anderson Cancer Center. Normally a 38% difference, in 500 patients, would have resulted in a much greater level of statistical significance. "Deaths occurring after three years are the most likely reason for the marginal level of statistical significance," Berry says.

Otis Brawley, chief medical officer of the American Cancer Society, says that he is "encouraged" by the data but warns, "I still think we need to be cautious."

"Please keep in mind, at best this is an effective treatment, it is not a cure for metastatic prostate cancer," says Brawley. "It may very well be an important new therapy. It is important that the scientific community digest this and do it right."

xxtrader

Cancer
Data Shows Provenge Extends Cancer Survival
Matthew Herper, 04.28.09, 02:01 PM EDT
Dendreon released some data on its prostate cancer drug, Provenge.

CHICAGO -- Dendreon released some dat ...
summer123 发表于 2009-4-28 14:16

如果超过22.5％，就等着这个股票过30吧，ONTY应该过5块5

xxtrader

NND,俺已经套利了卖了一半5000股ONTY在4.55,现在重新挂了5000股在4.2，现在4.22，又差2分钱，NND,赶紧给我FILLED了

PS。NND  FILLED600股

全部顺利FILLED

summer123

congrat now, 4.4

xxtrader

今天DNDN,和ONTY把我爽翻了，按惯例就知道消息出的当天早盘都会狂涨，快出消息了就会跌一下然后再飙，，俺都出了一半，然后低价又进了。就算现在它们都给我跌30％俺还有赚。嘿嘿

兄弟这两个股票要是有风险，俺其他的BIOTECH估计都要甩了。ONTY别捏太久因为它的肺癌第三阶段还没研究个结果出来，今天全靠DNDN的疫苗消息刺激，要快进快出，DNDN俺心目中的BIOTECH未来老大可以捏到老

bbbuyi

8# xxtrader


不是吧?刚刚DNDN狂跌45.20%至11.81刀.

autocdh

谢谢xxtrader ! 下次希望可以更早一点分享信息，稍晚一点就涨了很多，青蛙们已经不敢上船了。。。

sendmore11

xxtrader 老大的帖子总是很entertaining.

jiny2873

DNDN 盘后 +95%

yam

下午有事没有上来，错过了。不过，还是很感谢你的一声吼！

s0jv

顶老大

qiangge